BC002

BC002 is a biological drug developed by Sichuan Luzhou Buchang Biopharmaceutical, a subsidiary of Buchang Pharma. It is a biosimilar of etanercept, a recombinant human tumor necrosis factor (TNF) receptor-Fc fusion protein. BC002 consists of the extracellular ligand-binding portion of the human 75 kDa (p75) TNF receptor linked to the Fc portion of human IgG1. It functions as a TNF inhibitor by competitively binding to both TNF-alpha and lymphotoxin-alpha (TNF-beta), preventing their interaction with cell-surface TNF receptors and thereby downregulating the inflammatory cascade. The drug is primarily being developed for the treatment of autoimmune and inflammatory conditions, including rheumatoid arthritis and ankylosing spondylitis.

Other names

Recombinant human tumor necrosis factor receptor-antibody fusion proteinEtanercept biosimilar注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白